plerixafor
Mozobil	Pharmaceutical company: Genzyme Corporation www.mozobil.com

Pharmacologic classification: hematopoietic stem cell mobilizer
Therapeutic classification: hematologic drug
Pregnancy risk category: D

AVAILABLE FORMS
Injection: 20 mg/ml single-use vial

INDICATIONS AND DOSAGES
With granulocyte-colony stimulating factor (G-CSF) to mobilize stem cells for autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma—
Adults: Give four doses of G-CSF for 4 days; then give plerixafor 0.24 mg/kg subcutaneously 11 hours before apheresis for up to 4 consecutive days.
ADJUST-A-DOSE: For creatinine clearance 50 ml/minute or less, give 0.16 mg/kg subcutaneously daily before apheresis for up to 4 consecutive days.

CONTRAINDICATIONS AND CAUTIONS
None.

INTERACTIONS
None reported.

ADVERSE REACTIONS
CNS: dizziness, fatigue, headache, insomnia.
GI: diarrhea, flatulence, nausea, vomiting.
Musculoskeletal: arthralgia.
Skin: injection site reaction.

Reactions may be common, uncommon, life-threatening, or COMMON AND LIFE-THREATENING.

Home - Guest Registry - Customer Service

Brought to you by Lippincott Williams & Wilkins.
For help on how you should use this site, see our Disclaimer .

© Copyright 2010 by Lippincott Williams & Wilkins